| Nov 14 |
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
|
| Nov 13 |
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
|
| Nov 12 |
EyePoint price target lowered to $33 from $38 at Baird
|
| Nov 9 |
EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Nov 5 |
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing
|
| Oct 31 |
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
|
| Oct 30 |
EyePoint Pharmaceuticals prices $140M share offering
|
| Oct 30 |
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
|
| Oct 28 |
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
|
| Oct 28 |
EyePoint rises on interim data for mid-stage trial of its diabetic macular edema therapy
|
